Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07570147 | A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Single Ascending Doses of ABBV-1451 Infusions and Injections in Healthy Adult Participants | PHASE1 | RECRUITING | 90 | — | — | May 1, 2026 | Apr 1, 2027 | May 28, 2026 | 1 | United States |
An AE is defined as any untoward medical occurrence in a patient or clinical investigation in which a participant is administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study.
Cmax of ABBV-1451.
Tmax of ABBV-1451.
β of ABBV-1451.
t1/2 of ABBV-1451.
AUCt of ABBV-1451.
AUCinf of ABBV-1451.
| Arm | Type | Description |
|---|---|---|
| Part 1: Group 1 | EXPERIMENTAL | Participants will receive either single ascending doses of ABBV-1451 until they reach Dose A or placebo. |
| Part 1: Group 2 | EXPERIMENTAL | Participants will receive either single ascending doses of ABBV-1451 until they reach Dose B or placebo. |
| Part 1: Group 3 | EXPERIMENTAL | Participants will receive either single ascending doses of ABBV-1451 until they reach Dose C or placebo. |
| Part 1: Group 4 | EXPERIMENTAL | Participants will receive either single ascending doses of ABBV-1451 until they reach Dose A or placebo. |
| Part 1: Group 5 | EXPERIMENTAL | Participants will receive either single ascending doses of ABBV-1451 until they reach Dose C or placebo. |
| Part 1: Group 6 | EXPERIMENTAL | Participants will receive either single ascending doses of ABBV-1451 until they reach Dose TBD or placebo. |
| Part 2: Group 7 | EXPERIMENTAL | Japanese participants will receive a single dose of ABBV-1451 Dose C or placebo. |
| Part 2: Group 8 | EXPERIMENTAL | Han Chinese participants will receive a single dose of ABBV-1451 Dose C or placebo. |
| Name | Type | Description |
|---|---|---|
| ABBV-1451 | DRUG | Injection |
| Placebo | OTHER | Injection |
Inclusion Criteria: * A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile and a 12-lead ECG. * Applies to Part 2 only: * For Japanese participants: \-- Participant must be first or second-generation Japanese of fu...